We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » FDA Questions Merck’s Data for New Keytruda Indication
FDA Questions Merck’s Data for New Keytruda Indication
The FDA is unlikely to help Merck’s chances of getting a positive recommendation from the agency’s Oncology Drugs Advisory Committee today for its blockbuster drug Keytruda (pembrolizumab) for a new indication.